Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms AL18F-PSMA-137, [18F]AlF-PSMA-137 |
Target |
Action inhibitors |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingClinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prostatic Cancer | Clinical | China | 15 Jan 2021 | |
| PSMA-Positive Tumor | Clinical | China | 15 Jan 2021 |





